GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 19, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock, signaling confidence.
AI Summary
GSK plc announced on May 16, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- May 16, 2025 (date) — Date of purchase
FAQ
What was the specific number of GSK ordinary shares purchased on May 16, 2025?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK's corporate stockbroker.
What is the par value of GSK's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Is this a routine filing for GSK?
Yes, this is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, often used for ongoing reporting.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 19, 2025 regarding GSK plc (GLAXF).